Sterile fill-finish CDMOs in Europe: 106 compared (2026)
106 of the 255 contract development and manufacturing organisations in A4BEE’s European census list sterile fill-finish manufacturing among their capabilities. The largest, with revenue over €1bn, are ACS Dobfar, Boehringer BioXcellence, BSP Pharmaceuticals, Catalent, Famar, Fareva and 10 more. 34 sit between €250m and €1bn and 56 are smaller or niche.
By ownership: 45 family-owned, 24 private equity, 13 listed, 20 part of a pharma or industrial group and 4 state-owned. They are spread across 29 countries, led by Italy (12), Germany (11), Spain (11), the United Kingdom (10) and Greece (8). 52 of the 106 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
106 companies
Sterile fill-finish CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| ACS DobfarItalian anti-infectives specialist (1973). Vertically integrated: cephalosporin/carbapenem/penicillin APIs AND finished dosage on a CDMO basis. | Tribiano, Italy | Family-owned | Tier 1 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | high |
| Boehringer BioXcellenceUp to ~185,000 L mammalian capacity; a strategic pharma-owned biologics powerhouse. | Biberach, Germany | Part of a pharma or industrial groupBoehringer Ingelheim | Tier 1 | n/d (group €27.8 bn) | Monoclonal antibody, Microbial and protein, Sterile fill-finish | medium |
| BSP PharmaceuticalsLeading oncology CDMO: ADC conjugation + highly-potent aseptic fill-finish from clinical to commercial. Serves ~80 countries. | Latina, Italy | Family-ownedBraca family | Tier 1 | €532.7 m (2024) | Sterile fill-finish, Antibody-drug conjugate (ADC), Monoclonal antibody, Oral solid dose | high |
| CatalentTaken private by Novo Holdings (US$16.5 bn, Dec 2024); global but with EU sites. | Somerset, NJ, United States | Part of a pharma or industrial groupNovo Holdings | Tier 1 | ~US$4.4 bn FY2024 (global) | Biologics and biosimilars, Cell and gene therapy, Oral solid dose, Sterile fill-finish | medium |
| FamarOne of Europe's largest pure-play pharma/consumer-health CDMOs; 70+ yr legacy. Sterile injectables, eye drops, syrups, solids. 80 markets. | Alimos, Greece | Private equityMidEuropa | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| Fareva | Luxembourg, Luxembourg | Family-owned | Tier 1 | ~€2.2 bn | Sterile fill-finish, Oral solid dose, Small-molecule API, Monoclonal antibody | medium |
| Gedeon RichterPrimarily own-product/biosimilar pharma, but runs a real biologics CDMO arm (mammalian DS + fill-finish) and microbial CDMO via Richter-Helm. Group figures mostly non-CDMO. | Budapest, Hungary | Listed | Tier 1 | ~€2.1 bn (2023, group) | Biologics and biosimilars, Monoclonal antibody, Microbial and protein, Sterile fill-finish, Small-molecule API | high |
| HemofarmSTADA's largest manufacturing hub with a contract-manufacturing department, but production is overwhelmingly captive STADA rather than open-market CDMO. | Vršac, Serbia | Part of a pharma or industrial groupSTADA | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Insud Pharma (Chemo)Group-level entity. Chemo industrial division provides CMO/CDMO across most dosage forms incl. injectables. Parent of Liconsa and León Farma. | Madrid, Spain | Family-ownedGrupo Insud | Tier 1 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish, Biologics and biosimilars, Monoclonal antibody | high |
| Patheon ItaliaItaly CDMO sites of Thermo Fisher (Patheon). Sterile/lyo + high-potency + mRNA/LNP. | Ferentino, Italy | Part of a pharma or industrial groupThermo Fisher Scientific | Tier 1 | not disclosed | Sterile fill-finish, Biologics and biosimilars, mRNA and LNP, Small-molecule API | low |
| PharmathenVertically integrated developer of complex drug-delivery tech offering CDMO/co-development: long-acting injectables, SR oral solids, ophthalmics. | Pallini, Greece | Private equityPartners Group | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish, Peptide | high |
| Rovi Pharma Industrial ServicesBest-known Spanish injectables fill-finish CDMO; performed fill-finish of the Moderna COVID vaccine. Rebranded 'Rois' (2024). | Madrid, Spain | ListedLaboratorios ROVI | Tier 1 | Group ROVI ~€1.0 bn | Sterile fill-finish, Oral solid dose, Small-molecule API | high |
| Siegfried | Zofingen, Switzerland | Listed | Tier 1 | CHF 1.29 bn (2024) | Small-molecule API, Sterile fill-finish | low |
| SopharmaListed Bulgarian pharma with a dedicated CDMO business unit: sterile/non-sterile liquids, oral solids/semi-solids, API, packaging/serialization; handles controlled substances. | Sofia, Bulgaria | Listed | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | high |
| Vetter PharmaSterile fill-finish specialist (vials, syringes, cartridges). | Ravensburg, Germany | Family-owned | Tier 1 | n/d (large) | Sterile fill-finish | medium |
| Zentiva GroupLarge generics maker with an explicit B2B/CDMO arm (oral solids, sterile ampoules/vials, creams; APIs). Contract offering spans Prague and Bucharest. | Prague, Czechia | Private equityAdvent International | Tier 1 | ~€1.3 bn (group est.) | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| Adragos PharmaFSN Capital 'buy-and-build' roll-up acquiring sites from Sanofi/Fresenius Kabi. | Munich, Germany | Private equityFSN Capital | Tier 2 | n/d | Small-molecule API, Sterile fill-finish, Oral solid dose | medium |
| Aenova GroupMulti-site OSD/softgel/sterile group; acute data-silo profile across 14 sites. | Starnberg, Germany | Family-ownedKühne Holding | Tier 2 | n/d | Oral solid dose, Sterile fill-finish | medium |
| AlvotechReykjavik-based vertically-integrated biosimilars company (Nasdaq: ALVO). Core is its own biosimilar mAbs; 'Alvotech Contract Services' offers third-party biologics CDMO work. | Reykjavik, Iceland | Listed | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Sterile fill-finish | medium |
| Antibiotice IașiState-controlled, BVB-listed; world leader in Nystatin API by fermentation. Explicit EU-GMP contract manufacturing plus sterile injectables, capsules, tablets. | Iași, Romania | State-ownedRomanian state (majority) | Tier 2 | not disclosed | Small-molecule API, Microbial and protein, Oral solid dose, Sterile fill-finish | high |
| APL (Apotek Produktion & Laboratorier)State-owned; dual mandate of extemporaneous compounding for Sweden plus a commercial CDMO arm. | Stockholm, Sweden | State-ownedSwedish State | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | high |
| BiovetaLargest Czech veterinary immunobiological/pharma maker; dedicated contract-manufacturing function (vaccines, antisera, sterile forms). Primarily veterinary. | Ivanovice na Hané, Czechia | State-ownedCzech state (majority) | Tier 2 | not disclosed | Biologics and biosimilars, Viral vector and vaccine, Sterile fill-finish | medium |
| BluepharmaIntegrated CRDMO. OSD capacity ~2bn units/year plus complex injectables and LNP work. FDA-inspected 5×. | Coimbra, Portugal | Family-owned | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| CordenPharmaPeptide + lipid/LNP specialist riding the GLP-1 boom (e.g. Viking deal). | Basel, Switzerland | Private equity | Tier 2 | ~US$530 m | Peptide, mRNA and LNP, Sterile fill-finish, Small-molecule API | medium |
| Delpharm | Boulogne, France | Family-owned | Tier 2 | ~€650 m | Oral solid dose, Sterile fill-finish, Biologics and biosimilars | medium |
| DEMOPrimarily own-product (largest injectables supplier to Greek hospitals) but lists contract manufacturing. Own-API from 2019. | Krioneri, Greece | Family-owned | Tier 2 | not disclosed | Sterile fill-finish, Small-molecule API | medium |
| Doppel FarmaceuticiFull-service finished-dose CDMO: solids, semi-solids, liquids, sprays, and aseptic/terminally-sterilized injectable vials. | Cortemaggiore, Italy | Private equityTrilantic Europe | Tier 2 | €112.8 m (2024) | Oral solid dose, Sterile fill-finish | high |
| Fresenius Kabi Contract Manufacturing'Product Partnering' contract-manufacturing platform for sterile injectables, emulsions, liposomes and biologics. | Bad Homburg, Germany | ListedFresenius | Tier 2 | not disclosed | Sterile fill-finish, Biologics and biosimilars, Small-molecule API | medium |
| GeneticLeading Italian CDMO in respiratory + ophthalmic. BFS sterile monodose, eye drops, nasal sprays, pMDI/DPI inhalers. | Fisciano, Italy | Private equityRenaissance Partners | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| GrindeksMajor Baltic pharma that formally launched CDMO services (2025): API dev/manufacturing incl. HPAPIs, plus solid/liquid/semi-solid FDFs. Sterile injectables via Kalceks. | Riga, Latvia | Family-ownedKirovs Lipmans (majority) | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| Halden PharmaFormer Fresenius Kabi Halden sterile site; acquired 2024 by German Adragos/Prange. Norway's largest sterile-liquid site (IV bags, BFS, aseptic compounding). | Halden, Norway | Part of a pharma or industrial groupAdragos Pharma / Prange Group | Tier 2 | not disclosed | Sterile fill-finish | medium |
| Haupt Pharma LatinaAenova Group's designated central sterile site. Third-party sterile fill-finish plus beta-lactam injectables and oral solids. | Latina, Italy | Part of a pharma or industrial groupAenova Group | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose, Monoclonal antibody, Peptide, Biologics and biosimilars | low |
| IDT BiologikaViral vaccine/vector + oncolytic virus specialist with mRNA fill-finish. | Dessau-Roßlau, Germany | Part of a pharma or industrial groupSK bioscience | Tier 2 | n/d | Viral vector and vaccine, Sterile fill-finish, mRNA and LNP | medium |
| JGLLargest domestically-owned Croatian pharma and a genuine end-to-end sterile CMO — aseptic eye drops, nasal/bag-on-valve sprays. Expanding sterile capacity through 2026. | Rijeka, Croatia | Family-owned | Tier 2 | not disclosed | Sterile fill-finish | low |
| Laboratorios NormonPrimarily own-product generics leader; offers CMO services via its International Division. CMO is a secondary line. | Tres Cantos, Spain | Family-owned | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | medium |
| Laboratorios SalvatCDMO division specializes in sterile BFS liquids and single-dose ophthalmic/otic/nasal formulations. | Barcelona, Spain | Family-ownedPeris family | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| Meribel Pharma SolutionsFormed 2025 from Synerlab + 7 Recipharm sites; classic multi-site integration play. | London, United Kingdom | Private equityBlue Wolf | Tier 2 | ~€300 m est. | Sterile fill-finish, Oral solid dose | medium |
| Morpho (Alfasigma CDMO)Alfasigma's dedicated third-party CDMO unit (rebranded 'Morpho' 2024). Sterile injectables, lyophilized products, vaccines, oral solids. | Bologna, Italy | Part of a pharma or industrial groupAlfasigma | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars | high |
| NextPharma | London, United Kingdom | Private equity | Tier 2 | ~€229 m | Oral solid dose, Sterile fill-finish | medium |
| NorthX BiologicsBiologics CDMO built on the former Cobra Biologics Matfors site; Swedish national innovation hub for ATMPs. | Matfors, Sweden | Private equityFlerie Invest | Tier 2 | not disclosed | Microbial and protein, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy, Monoclonal antibody, Sterile fill-finish | low |
| Quotient SciencesFull-service third-party CDMO (drug substance/product + clinical). UK-HQ under European PE. | Nottingham, United Kingdom | Private equityPermira | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Peptide, Sterile fill-finish | low |
| RafarmEnd-to-end CDMO/CMO (50 yrs); third-party contract manufacturing of sterile ophthalmics and complex injectables (robotic sterile lines). | Paiania, Greece | Family-owned | Tier 2 | not disclosed | Sterile fill-finish | high |
| Recipharm | Stockholm, Sweden | Private equityEQT | Tier 2 | €827 m (2024) | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine | high |
| Reig JofreMarket leader in complex generics; CDMO covers sterile/lyophilized injectables plus beta-lactam antibiotics in segregated facilities. | Sant Joan Despí, Spain | Listed | Tier 2 | €339 m (2024) | Sterile fill-finish, Small-molecule API, Oral solid dose | high |
| Saneca PharmaceuticalsSlovakia's largest pharma and a genuine API + FDF CDMO (carve-out of former Zentiva/Sanofi API business). Opiate/narcotic API specialist plus oral solids. | Hlohovec, Slovakia | Private equity | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| TAPI CroatiaTeva's API arm operates the Savski Marof site with a rare sterile-API facility explicitly offering third-party CDMO services. | Savski Marof, Croatia | Part of a pharma or industrial groupTeva | Tier 2 | not disclosed | Small-molecule API, Sterile fill-finish | high |
| Tecnimede (Atlantic Pharma)Primarily own-product/generics group that also offers contract manufacturing (solids/semi-solids/liquids). CMO secondary. | Sintra, Portugal | Family-ownedTecnimede Group | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Unither PharmaceuticalsWorld leader in Blow-Fill-Seal sterile unit-dose liquids; also effervescent/oral formats. | Amiens, France | Private equityArdian | Tier 2 | €371 m (2022) | Sterile fill-finish, Oral solid dose | high |
| Vianex90+ yr firm; long-standing contract manufacturer (exclusive local/export production for MSD since 1983). Cephalosporins + solids/injectables. | Nea Erythraia, Greece | Family-ownedGiannakopoulos family | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| Xellia PharmaceuticalsFermentation-based non-beta-lactam anti-infectives; APIs + FDF to 500+ pharma companies, plus CMO/CDMO services. Phasing out Copenhagen manufacturing. | Copenhagen, Denmark | Part of a pharma or industrial groupNovo Holdings | Tier 2 | not disclosed | Small-molecule API, Sterile fill-finish, Microbial and protein | high |
| Amatsigroup (Eurofins)French sterile CDMO within the Eurofins network. | Toulouse, France | Part of a pharma or industrial groupEurofins | Tier 3 | n/d | Sterile fill-finish | low |
| Anfarm HellasEU-GMP manufacturer offering 3rd-party manufacturing / CDMO / tech transfer. Specializes in lyophilised products, liquid injectables, beta-lactams. | Kifissia, Greece | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| ArdenaNanomedicine/LNP + drug-substance/product + bioanalytical CDMO. | Ghent, Belgium | Private equityGHO Capital | Tier 3 | n/d | mRNA and LNP, Oral solid dose, Sterile fill-finish | medium |
| Bath ASUOne of the UK's largest independent aseptic 'specials' manufacturers — patient-specific chemo, CIVAS, PCA injectables for 220+ NHS trusts. | Corsham, United Kingdom | Private equity | Tier 3 | not disclosed | Sterile fill-finish | medium |
| BespakDrug-delivery / combination-product CDMO (pMDI valves, DPI devices, inhaled/nasal). Spun out of Recipharm into a standalone EQT-backed CDMO (2024). | King's Lynn, United Kingdom | Private equityEQT | Tier 3 | not disclosed | Sterile fill-finish | medium |
| BimedaIrish family-owned global animal-health company; contract/private-label veterinary manufacturing (drenches, nutritional liquids, ecto-parasiticides). | Dublin, Ireland | Family-owned | Tier 3 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | medium |
| Bioindustria L.I.M.Own + third-party manufacturing. Sterile injectable/freeze-dried solutions and non-sterile tablets/capsules; also an API dept. | Novi Ligure, Italy | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | high |
| BiotonAmong the world's top-eight commercial manufacturers of recombinant human insulin. | Warsaw, Poland | Listed | Tier 3 | n/d | Biologics and biosimilars, Sterile fill-finish | medium |
| CenexiSterile fill-finish specialist (injectables, ampoules, HPAPI sterile). | Fontenay-sous-Bois, France | Private equityCathay Capital | Tier 3 | €191 m (2023) | Sterile fill-finish | high |
| Chanelle PharmaIreland's largest indigenous generics maker (human + veterinary); explicitly offers CMO/CDMO services alongside own generics. | Loughrea, Ireland | Private equityExponent Private Equity | Tier 3 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| Combino PharmGenerics developer that licenses out dossiers and offers third-party contract manufacturing, mainly via its Malta plant. | Sant Joan Despí, Spain | Family-ownedCorporación Medichem | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | medium |
| Croma-PharmaFamily-owned hyaluronic-acid specialist that contract-manufactures HA prefilled syringes for ortho/ophthalmology partners. | Leobendorf, Austria | Family-ownedPrinz family | Tier 3 | not disclosed | Sterile fill-finish | medium |
| CuridaFrom a 2015 buyout of Takeda's Elverum sterile-liquids plant. BFS + nasal-spray fill-finish CDMO, plus a small Bio-CDMO unit (mAbs for preclinical/diagnostic use). | Elverum, Norway | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Biologics and biosimilars | high |
| EVER PharmaSpecialty-injectables pharma that also runs a full CDMO for complex sterile injectables (cytotoxics, hormones, suspensions). | Unterach, Austria | Family-ownedB.F.H. Privatstiftung | Tier 3 | not disclosed | Sterile fill-finish | medium |
| GenIbet BiopharmaceuticalsBiologics CDMO: microbial, cell culture, viral process dev + cGMP manufacture plus fill-finish. Made mRNA material for Moderna. | Oeiras, Portugal | Part of a pharma or industrial groupRecipharm | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, Viral vector and vaccine, Cell and gene therapy, mRNA and LNP, Sterile fill-finish | high |
| GP PharmCDMO focused on highly complex injectables: peptides, oligonucleotides, hormones, liposomes and microspheres. FDA-inspected. | Sant Quintí de Mediona, Spain | Family-ownedParente family | Tier 3 | not disclosed | Peptide, Sterile fill-finish | high |
| GTP BiowaysBiologics CDMO (mAbs, proteins, nanodrugs, ADCs, fill-finish). Acquired by Italy's Olon; now Olon France. | Toulouse, France | Part of a pharma or industrial groupOlon Group | Tier 3 | ~€12 m | Monoclonal antibody, Biologics and biosimilars, Antibody-drug conjugate (ADC), Microbial and protein, Sterile fill-finish | high |
| Helsinn Birex PharmaceuticalsIrish-registered entity primarily making the Swiss parent's products; advertises third-party OSD + gel/cream contract manufacturing. Closer to captive site. | Dublin, Ireland | Part of a pharma or industrial groupHelsinn Group (Switzerland) | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | low |
| Iasis PharmaProvides CDMO/CMO services alongside own products (since 1985). Broad dosage forms; exports to 36 countries. | Koropi, Greece | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| IBI LorenziniAseptic manufacturing of sterile injectables (specialist in sterile penicillins/cephalosporins) plus oral, topical and biotech. | Aprilia, Italy | Family-ownedIbigen Group | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Monoclonal antibody, Peptide | high |
| IMUNA PHARMContract manufacturer of sterile infusion and dialysis solutions in single/multi-chamber bags; own brands plus products for multinationals. | Šarišské Michaľany, Slovakia | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| InnoCore PharmaceuticalsDrug-delivery CDMO for long-acting injectables (microspheres, implants, depot gels) via proprietary SynBiosys polymers. | Groningen, Netherlands | Family-owned | Tier 3 | not disclosed | Peptide, Biologics and biosimilars, Sterile fill-finish | high |
| KeveltEU-GMP Estonian maker of sterile small-volume parenterals, sterile semi-solids and biological medicinal products; seeks contract-manufacturing partnerships. | Tallinn, Estonia | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Biologics and biosimilars | high |
| Klocke Pharma-ServiceContract manufacturing/packaging of solid dosage plus aseptic liquids and lyophilisates. | Appenweier, Germany | Family-ownedKlocke Gruppe | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| LabianaCDMO/CMO for human and animal health; sterile liquids, non-sterile solids, sterile injectable + freeze-dried forms. BME Growth-listed. | Corbera de Llobregat, Spain | Listed | Tier 3 | €66 m (2024) | Sterile fill-finish, Oral solid dose | high |
| Laboratoires SteropSterile injectables/ampoules maker (est. 1947); own essential-medicines portfolio plus CMO services. ~75% export. | Brussels, Belgium | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| Laboratorios Alcalá Farma'Leading CDMO in Spain' (20+ yrs); broad dosage forms incl. soft-gel caps, stick-packs, sterile/injectable, lyophilised. Owned by Synerlab. | Alcalá de Henares, Spain | Part of a pharma or industrial groupSynerlab | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| Laboratórios BasiPortuguese pharma (since 1956) offering contract manufacturing for injectables, gels, creams and oral solutions. CMO secondary. | Mortágua, Portugal | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | medium |
| LavipharmSpecialist developer/manufacturer of transdermal drug delivery systems (TDDS) — one of few integrated TDDS lines in Europe; CDMO services. | Peania, Greece | Listed | Tier 3 | not disclosed | Sterile fill-finish | medium |
| LusomedicamentaManufacturer of solid, liquid and semi-solid dosage forms; explicitly lists contract manufacturing. Exports to 47 countries. | Queluz, Portugal | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| MabionPivoted from biosimilar developer to biologics CDMO; anchor Novavax COVID-antigen contract + Sartorius cooperation. | Konstantynów Łódzki, Poland | Listed | Tier 3 | n/d (Novavax-driven, volatile) | Biologics and biosimilars, Monoclonal antibody, Sterile fill-finish | low |
| Magle ChemoswedVertically-integrated CDMO/CMO for pharma and med-tech: intermediates → APIs, niche formulation, fill-finish, QP release. FDA-inspected. | Malmö, Sweden | Listed | Tier 3 | not disclosed | Small-molecule API, Sterile fill-finish | high |
| MedinfarOperates a CMO/CDMO industrial unit (~20 yrs) alongside its own portfolio; finished dosage forms, galenic, packaging. | Amadora, Portugal | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| mibe ArzneimittelDermapharm's main production site (tablets, sterile ampoules/lyo, ointments); primarily in-house, expanding third-party. | Brehna, Germany | Part of a pharma or industrial groupDermapharm Holding | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | low |
| NerPharMaHPAPI/oncology CDMO offering integrated drug substance + drug product: injectables and oral solids. EMA + FDA accredited. | Nerviano, Italy | Part of a pharma or industrial groupBenta Group (Lebanon) | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Small-molecule API | high |
| NextPharma GöttingenGerman solid-dosage sites (incl. allphamed Pharbil) of the privately held European NextPharma group. | Göttingen, Germany | Private equity | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | low |
| Northway BiotechCEE cost-competitive biologics CDMO scaling to 5,000 L stainless steel. | Vilnius, Lithuania | Family-owned | Tier 3 | n/d | Monoclonal antibody, Microbial and protein, Biologics and biosimilars, Sterile fill-finish, Viral vector and vaccine, Cell and gene therapy | medium |
| Nova LaboratoriesIndependent aseptic-processing CDMO + 'Specials' supplier; sterile fill-finish for clinical-trial medicines. | Leicester, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Biologics and biosimilars, Microbial and protein | medium |
| Ovelle PharmaceuticalsFamily-owned (since 1934). Own dermatology brands plus CMO/CDMO manufacturing of cosmetic, medical-device and licensed products. | Dundalk, Ireland | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | medium |
| Pharma-SkanIndependent CMO producing/filling liquid and sterile pharmaceuticals and oral liquids for human and veterinary use. | Skanderborg, Denmark | Private equityBrygge Partners | Tier 3 | not disclosed | Sterile fill-finish | medium |
| PharmpurIndependent family-owned contract manufacturer of sterile liquids in syringes/vials (ophthalmic focus). | Königsbrunn, Germany | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | low |
| PierrelListed Italian company. Contract-manufacturing division does aseptic small-volume parenteral fill for external clients. | Capua, Italy | Listed | Tier 3 | €53.7 m (2024) | Sterile fill-finish | high |
| Pinewood HealthcareIrish-HQ operating entity with a dedicated contract-manufacturing division (non-beta-lactam sachets/powders, oral liquids, creams). Owned by Wockhardt (India). | Ballymacarbry, Ireland | Part of a pharma or industrial groupWockhardt (India) | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| Polfa TarchominState-owned; anti-infectives + insulin + ampoules/vials/lyo. | Warsaw, Poland | State-owned | Tier 3 | n/d | Small-molecule API, Biologics and biosimilars, Sterile fill-finish | medium |
| PrasfarmaCMO/CDMO specialized in cytostatics, HPAPI and oncology; aseptic fill/lyophilization plus solid forms. Annex-1. | Cerdanyola del Vallès, Spain | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| Praxis PharmaceuticalCDMO for dev + contract manufacturing of liquid and lyophilised sterile injectables incl. biologics and orphan drugs. Annex-1. | Vitoria-Gasteiz, Spain | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| PSMFamily-run aseptic fill-and-finish CDMO; new facility passed EU GMP Annex 1. | Schiffweiler, Germany | Family-ownedTrennheuser family | Tier 3 | not disclosed | Sterile fill-finish | medium |
| Rechon Life ScienceSterile-injectables CDMO (ampoules, vials, cartridges, PFS) plus nasal/oral sprays. From Ferring's former Malmö plant; Chinese-owned. | Malmö, Sweden | Part of a pharma or industrial groupShanghai Dongbao | Tier 3 | not disclosed | Sterile fill-finish | high |
| Richter PharmaFamily pharma group with a GMP contract-manufacturing unit for injectable solutions and semi-solids. | Wels, Austria | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | medium |
| S.A.L.F. Laboratorio FarmacologicoInjectable/infusion sterile solutions (ampoules, bottles, bags) — own portfolio plus explicit contract manufacturing. Since 1921. | Cenate Sotto, Italy | Family-ownedAngeletti family | Tier 3 | not disclosed | Sterile fill-finish | high |
| Sanochemia PharmazeutikaCDMO for sterile injectables and small-molecule APIs; also a leading MRI/CT contrast-agent maker. | Neufeld an der Leitha, Austria | Private equityEOSS Industries consortium | Tier 3 | not disclosed | Small-molecule API, Sterile fill-finish | high |
| Symbiosis Pharmaceutical ServicesIndependent sterile aseptic fill-finish CDMO (clinical + commercial): mAbs, ATMPs, viral vectors, ADCs, vaccines. FDA-inspected. | Stirling, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Antibody-drug conjugate (ADC), Biologics and biosimilars, Cell and gene therapy, Small-molecule API | medium |
| ten23 healthSterile drug-product formulation & fill-finish CDMO (biologics, cell & gene therapy); absorbed swissfillon (Visp) in 2021. | Basel, Switzerland | Private equity3i Group | Tier 3 | not disclosed | Sterile fill-finish, Biologics and biosimilars, Cell and gene therapy | high |
| Upperton Pharma SolutionsSpray-drying specialist CDMO: formulation + dosage-form dev for oral, nasal, pulmonary and sterile forms (small molecules + biologics). | Nottingham, United Kingdom | Private equityInflexion | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish, Biologics and biosimilars | high |
| Wasdell GroupUK contract packaging + CDMO (solid/non-sterile dosage, clinical + commercial). Wound down Irish operations in 2024 — verify current status. | Swindon, United Kingdom | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Wockhardt UK (CP Pharmaceuticals)UK operating entity; third-party contract manufacture of sterile injectables (vials, cartridges, ampoules, lyo) alongside own generics. | Wrexham, United Kingdom | Part of a pharma or industrial groupWockhardt (India) | Tier 3 | not disclosed | Sterile fill-finish, Small-molecule API, Biologics and biosimilars | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)